[EN] 5-(THIOPHEN-2-YL)-1H-TETRAZOLE DERIVATIVES AS BCKDK INHIBITORS USEFUL FOR TREATING VARIOUS DISEASES [FR] DÉRIVÉS DE 5-(THIOPHÉN-2-YL) -1H-TÉTRAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE BCKDK UTILES POUR LE TRAITEMENT DE DIVERSES MALADIES
[EN] 5-(THIOPHEN-2-YL)-1H-TETRAZOLE DERIVATIVES AS BCKDK INHIBITORS USEFUL FOR TREATING VARIOUS DISEASES [FR] DÉRIVÉS DE 5-(THIOPHÉN-2-YL) -1H-TÉTRAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE BCKDK UTILES POUR LE TRAITEMENT DE DIVERSES MALADIES
[EN] SUBSTITUTED THIOPENES OR FURANS AS ESTROGEN RECEPTOR LIGANDS<br/>[FR] THIOPHÈNES OU FURANNES SUBSTITUÉS COMME LIGANDS DE RÉCEPTEURS DES OESTROGÈNES
申请人:KAROBIO AB
公开号:WO2012022776A1
公开(公告)日:2012-02-23
The invention provides: a compound of Formula (I) or a pharmaceutically acceptable ester, amide, or salt thereof, including a salt of such an ester or amide, wherein A, B, R1, R2, R4, R5, R6 and R7 are as defined in the specification. The indention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.
[EN] 5-(THIOPHEN-2-YL)-1H-TETRAZOLE DERIVATIVES AS BCKDK INHIBITORS USEFUL FOR TREATING VARIOUS DISEASES<br/>[FR] DÉRIVÉS DE 5-(THIOPHÉN-2-YL) -1H-TÉTRAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE BCKDK UTILES POUR LE TRAITEMENT DE DIVERSES MALADIES
申请人:PFIZER
公开号:WO2020261144A1
公开(公告)日:2020-12-30
Described herein are compounds of Formula (I), wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
The optimization of a series of thieno[3,2-b]thiophene-2-carboxylic acid derivatives for agonist activity against the GPR35 is reported. Compounds were optimized to achieve beta-arrestin-biased agonism for developing probe molecules that may be useful for elucidating the biology and physiology of GPR35. Compound 13 was identified to the most potent GPR35 agonist, and compounds 30 and 36 exhibited the highest efficacy to cause beta-arrestin translocation. (C) 2012 Elsevier Ltd. All rights reserved.